Abstract 【Objective】To explore the clinical value of miRNA-208b (miR-208b) in predicting left ventricular remodeling after acute myocardial infarction (AMI). 【Methods】A total of 167 AMI patients admitted to our hospital from November 2018 to September 2020 were selected, and they were divided into a remodeling group (n=62) and a non remodeling group (n=105) based on whether there was left ventricular remodeling during follow-up. The clinical indicators and expression of miR-208b, as well as the correlation between miR-208b and left ventricular remodeling, were analyzed in two groups of patients. The receiver operating characteristic (ROC) curve analysis was used to evaluate the value of miR-208b in left ventricular remodeling in AMI patients. 【Results】The final left ventricular end diastolic volume (LVEDV), left ventricular end diastolic volume increase (LVEDV), low-density lipoprotein cholesterol (LDL-C), cardiac troponin I (cTnI), and brain natriuretic peptide (BNP) levels of patients in the reconstruction group were higher than those in the non reconstruction group, and the expression level of miR-208b was lower than that in the non reconstruction group, with statistical significance (P<0.05). Pearson correlation analysis showed that miR-208b was negatively correlated with BNP and final LVEDV (P<0.05), and positively correlated with cTnI (P<0.05). ROC curve analysis showed that miR-208b had a high value in predicting left ventricular remodeling after AMI, with an area under the curve (AUC) (95%CI) of 0.80(0.73-0.87) and an optimal diagnostic threshold of 3.17. Binary logistic regression analysis showed that miR-208b, cTnI, LVEDV, and BNP were closely related to left ventricular remodeling (P<0.05). 【Conclusion】miR-208b is a potential clinical indicator for diagnosing left ventricular remodeling after AMI, and clinical physicians can estimate the risk of left ventricular remodeling in AMI patients based on miR-208b expression.
NIU Hongmei. The Clinical Value of miRNA-208b in Predicting Left Ventricular Remodeling after AMI[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(4): 555-557.
[1] 崔秋利,赵云清.miRNA-21在急性心肌梗死发生、发展中的作用机制[J].医学临床研究,2023,40(4):600-603. [2] 曹润峰,沈立. miRNA在心肌梗死中的作用及其机制研究进展[J].中华细胞与干细胞杂志(电子版),2019,9(6):363-368. [3] ZHAO D D. Cardiomyocyte derived miR-328 promotes cardiac fibrosis by paracrinely regulating adjacent fibroblasts [J].Cell Physiol Biochem,2018,46(4):1555-1565. [4] VAN R E,QUIAT D,JOHNSON B A,et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance [J].Dev Cell,2009,17(5):662-673. [5] ZHOU C Y,CUI Q T,SU G B,et al. MicroRNA-208b alleviates post-infarction myocardial fibrosis in a rat model by inhibiting GATA4[J].Med Sci Monit,2016,22:1808-1816. [6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2019,47(10):766-783. [7] LANG R M,BADANO L P,MOR-AVI V,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the european association of cardiovascular imaging [J].Eur Heart J Cardiovasc Imaging,2015,16(3):233-270. [8] ZILE M R,MEHURG S M,ARROYO J E,et al. Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction [J].Circ Cardiovasc Genet,2011,4(6):614-619. [9] 王海斌,薛军,高晓丽,等. 糖尿病对老年非ST段抬高型心肌梗死患者冠状动脉介入治疗后左心室重塑及短期预后的影响[J].中国急救复苏与灾害医学杂志,2017,12(1):27-30. [10] 赵鸿泽,谢飞,刘剑雄. 心梗后再灌注治疗患者心室重塑影响因素的研究进展[J].实用心电学杂志,2019,28(4):273-278. [11] 薛寒冰,薛一南,曹建.冠心病患者miRN A-221-3p表达情况及临床诊断价值分析[J].医学临床研究,2020,37(11):1664-1666. [12] 陈海滨,张新禄,梁鸿彬,等. 减阻剂改善自发性高血压大鼠左心室重塑[J].中华老年学杂志,2016,36(9):2049-2051. [13] YVAN D,MÉLANIE V,EMELINE G,et al. Use of circulating microRNAs to diagnose acute myocardial infarction [J].Clin Chem,2012,58(3):559-567. [14] KIM J S,KYOUNGJUNE P,TAE S G,et al. Prognostic value of microRNAs in coronary artery diseases: a meta-analysis[J].Yonsei Med J,2018,59(4):495-500. [15] WANG L Y,TANG S M,WANG Z R,et al. The administration of dexmedetomidine changes microRNA expression profiling of rat hearts[J].Biomed Pharmacother,2019,120:109463.
2024, Vol. 41 
